NRBO NeuroBo Pharmaceuticals Inc: רווח נקי למניה אחת בשנים עשר החודשים האחרונים

NeuroBo Pharmaceuticals (NRBO) is developing through R&D projects under the control of an Asian holding company. The trend of the percentage change in EPS YoY TTM demonstrates local dynamics, where 97.90 describes the current status of the metric. However, expansion is hindered by fierce competition with pharma market behemoths and geopolitical complexities regarding patent law and component supplies, which creates risks for the long-term growth of the share price.
NRBO (NeuroBo): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This metric measures the rate of change in net income per share, stripping the financial result of one-time factors. By analyzing the 12-month YoY EPS trend, an investor assesses the efficiency of capital generation. The metric is sensitive to fluctuations in operating expenses and profit volume. For NeuroBo Pharmaceuticals (NRBO), this reflects the cost of outsourcing research to external laboratories. Diversifying contract partners stabilizes this trend.